Judge Dismisses Federal Death Penalty Charges in UnitedHealthcare CEO Murder Case

A federal judge has delivered a pivotal ruling in the high-profile case against Luigi Mangione, the man accused of assassinating UnitedHealthcare chief executive Brian Thompson. U.S. District Judge Margaret Garnett dismissed two federal firearms charges that carried the possibility of capital punishment, ensuring Mangione will not face the death penalty if convicted in the federal proceeding. This decision, however, does not absolve him of the core allegations, as he still confronts serious state murder charges and remaining federal counts.

The ruling centers on a technical legal interpretation that has profound implications for the case's potential outcomes. Judge Garnett, an appointee of President Joe Biden, determined that two of the four federal charges did not meet "the federal statutory definition of a 'crime of violence' as matter of law." She emphasized that her decision was "solely to foreclose the death penalty as an available punishment to be considered by the jury," not a dismissal of the case itself. The prosecution has been granted 30 days to challenge this aspect of the ruling.

Remaining Charges and Legal Proceedings

Despite the dismissal of the death penalty-eligible charges, Mangione's legal jeopardy remains substantial. He still faces federal stalking charges, which carry a maximum sentence of life in prison. Furthermore, New York state prosecutors have brought nine separate charges against him, including second-degree murder. This creates a complex legal landscape where Mangione must defend himself in both federal and state courts, with the state seeking a trial as soon as July 2024, potentially ahead of the federal proceedings scheduled for September.

The evidence in the case includes items recovered from Mangione's backpack at the time of his arrest at a McDonald's in Altoona, Pennsylvania. Judge Garnett ruled that prosecutors may present this evidence to the jury, overruling defense objections. The backpack allegedly contained a gun, fake identification documents, and a notebook with writings that detailed grievances against the U.S. healthcare system. This evidence is central to the prosecution's theory of motive, suggesting the shooting was a "premeditated, cold-blooded assassination" targeting a healthcare industry executive.

Case Background and Alleged Motive

The case stems from the December 4, 2024, shooting of Brian Thompson, a 50-year-old father of two, as he walked into a Manhattan hotel for an annual investor conference. Investigators say Thompson was shot from behind by a masked gunman in a brazen attack that shocked New York City and the corporate world. Shell casings recovered at the scene bore the handwritten words "deny," "defend," and "depose"—phrases that law enforcement sources suggest may reference the "three Ds of insurance," tactics allegedly used by companies to reject patient payment claims.

Luigi Mangione, an Ivy League graduate from a wealthy Maryland family, was arrested days after the shooting and has pleaded not guilty to all federal and state charges. The case has attracted additional bizarre developments, including the recent arrest of a Minnesota man, Mark Anderson, for allegedly impersonating an FBI agent in an attempt to free Mangione from the Brooklyn jail where he is being held. Anderson was reportedly carrying a barbecue fork and pizza cutter during the attempted jailbreak and is now detained at the same facility as Mangione.

Legal Implications and Next Steps

The judge's ruling represents both a setback for federal prosecutors, who sought the death penalty option, and a partial victory for the defense. Mangione's attorney, Karen Agnifilo, thanked the court for "this incredible decision" and stated, "We're all very relieved. We're prepared, and have been prepared, to fight this case, and we look forward to fighting this case." The legal team had previously sought to dismiss the backpack evidence, arguing authorities obtained it illegally without a warrant, but Judge Garnett rejected that motion.

Jury selection for the federal trial is scheduled to begin on September 8, 2025, with opening statements expected to start on October 13, 2025. However, the timeline could be complicated by New York state's efforts to try Mangione sooner. The dual-track prosecution creates a rare legal scenario where a defendant faces parallel proceedings in different jurisdictions for the same underlying conduct. The dismissal of the death penalty charges simplifies the federal trial's penalty phase but does not affect the state's ability to pursue its own case independently.

As the case moves forward, it continues to raise questions about corporate security, the vulnerability of high-profile executives, and the intersection of personal grievance with violent action. The alleged connection to healthcare system criticisms adds a layer of social commentary to what would otherwise be a straightforward violent crime. The legal proceedings will likely continue to attract significant media attention as they unfold in both federal and New York state courts over the coming months.